Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 for knee pain due to osteoarthritis
ACTRN12616001104448Phase 2Completed
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Aug 2016
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Zygel in osteoarthritis (OA) (3 arms), sponsored by Zynerba Pharmaceuticals. Primary endpoints: Change in weekly mean of 24-hour average worst pain score, Change in WOMAC score and 1 more. Started Aug 2016; status: completed.
02
Drugs
Zygel
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12616001104448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001104448.